Evidence map›Paper›PMID 40665909›Full record

ArticleCirculation2025

PIEZO1 Overexpression in Hereditary Hemorrhagic Telangiectasia Arteriovenous Malformations.

Hyojin Park, Sungwoon Lee, Jessica Furtado, Mark Robinson, Richard J Antaya, S Paul Oh, Young-Kwon Hong, Martin A Schwartz, Lawrence H Young, Anne Eichmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Hyojin ParkCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-3671-8618
Sungwoon LeeCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.
Jessica FurtadoCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.
Mark RobinsonDepartment of Internal Medicine, Section of Hematology and Medical Oncology (M.R., L.H.Y.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0003-2363-6047
Richard J AntayaDepartments of Dermatology, Pediatrics, and Nursing (R.J.A.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-8557-5986
S Paul OhDepartment of Translational Neuroscience, Barrow Aneurysm & AVM Research Center, Barrow Neurological Institute, Phoenix, AZ (S.P.O.).ORCID 0000-0002-3833-0342
Young-Kwon HongDepartment of Surgery, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles (Y.-K.H.).ORCID 0000-0001-8245-875X
Martin A SchwartzCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0002-2071-1243
Lawrence H YoungCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0003-0295-7298
Anne EichmannCardiovascular Research Center, Department of Internal Medicine (H.P., S.L., J.F., M.A.S., L.H.Y., A.E.), Yale University School of Medicine, New Haven, CT.ORCID 0000-0001-5563-210X

Funding

Flow regulation of the Alk1/Eng pathway in vascular homeostasis and diseaseR01HL169510 · NHLBI · YALE UNIVERSITY · PI Anne Christine Eichmann, Martin A Schwartz · 2023 to 2026
$3.0M
NHLBI NIH HHS R01 HL169510
6 · The paper itself

Abstract

backgroundHereditary hemorrhagic telangiectasia is an inherited vascular disorder characterized by arteriovenous malformations (AVMs). Loss-of-function variations in activin receptor-like kinase 1 (

methodsSingle-cell RNA sequencing of endothelial-specific

resultsA cluster of

conclusionsPIEZO1 expression and signaling are elevated in type 2 hereditary hemorrhagic telangiectasia. PIEZO1 blockade reduces AVM formation and alleviates cellular and molecular hallmarks of ALK1-deficient cells. This finding provides new insights into the mechanistic underpinnings of ALK1-related vascular diseases and identifies potential therapeutic targets to prevent AVMs.

Indexed as

Arteriovenous MalformationsIon ChannelsTelangiectasia, Hereditary HemorrhagicActivin Receptors, Type IActivin Receptors, Type IIAnimalsEndothelial CellsHumansMaleMiceMice, KnockoutProto-Oncogene Proteins c-aktSignal TransductionVascular Endothelial Growth Factor Receptor-2Activin Receptors, Type IActivin Receptors, Type IIACVRL1 protein, humanAcvrl1 protein, mouseIon ChannelsPIEZO1 protein, humanPiezo1 protein, mouseProto-Oncogene Proteins c-aktVascular Endothelial Growth Factor Receptor-2ALK1arteriovenous malformationsmechanotransduction, cellularPIEZO1 protein, humanPIEZO1 protein, mousetelangiectasia, hereditary hemorrhagic

Identifiers

PMID40665909
PMCPMC12270330

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.